SAG — S-antigen visual arrestin

The SAG gene provides instructions for making a protein called S-arrestin, which is essential for normal vision. This protein is found primarily in the retina, the light-sensitive tissue at the back of the eye. When light enters the eye, it triggers a chain reaction in the retinal cells (photoreceptors) that sends visual signals to the brain. S-arrestin acts like a brake, stopping this reaction so the cells can reset and be ready for the next flash of light. Without this braking mechanism, the cells remain activated for too long, which can damage them over time. When the SAG gene is mutated, it can cause different types of inherited retinal diseases. If a person inherits two non-working copies of the gene (one from each parent), they may develop Oguchi disease, a condition that causes night blindness from a young age but usually does not get worse over time. In other cases, inheriting two mutated copies can lead to a more severe condition called retinitis pigmentosa (RP), which causes progressive loss of night and peripheral vision, eventually affecting central vision as well. Interestingly, some specific mutations in the SAG gene only require one altered copy (inherited from just one parent) to cause retinitis pigmentosa. This is known as an autosomal dominant inheritance pattern. For patients and families, knowing the specific mutation in the SAG gene is important because it helps doctors predict how the disease might progress and determines the chances of passing the condition on to children. Genetic counseling can provide valuable guidance and support for families navigating these diagnoses.

Gene description: Encodes S-arrestin, a protein involved in the deactivation of rhodopsin in photoreceptor cells.

Patient and family guide: The SAG gene provides instructions for making a protein called S-arrestin, which is essential for normal vision. This protein is found primarily in the retina, the light-sensitive tissue at the back of the eye. When light enters the eye, it triggers a chain reaction in the retinal cells (photoreceptors) that sends visual signals to the brain. S-arrestin acts like a brake, stopping this reaction so the cells can reset and be ready for the next flash of light. Without this braking mechanism, the cells remain activated for too long, which can damage them over time. When the SAG gene is mutated, it can cause different types of inherited retinal diseases. If a person inherits two non-working copies of the gene (one from each parent), they may develop Oguchi disease, a condition that causes night blindness from a young age but usually does not get worse over time. In other cases, inheriting two mutated copies can lead to a more severe condition called retinitis pigmentosa (RP), which causes progressive loss of night and peripheral vision, eventually affecting central vision as well. Interestingly, some specific mutations in the SAG gene only require one altered copy (inherited from just one parent) to cause retinitis pigmentosa. This is known as an autosomal dominant inheritance pattern. For patients and families, knowing the specific mutation in the SAG gene is important because it helps doctors predict how the disease might progress and determines the chances of passing the condition on to children. Genetic counseling can provide valuable guidance and support for families navigating these diagnoses.

Gene function: SAG, or S-arrestin, is a key protein in the visual cycle, responsible for quenching the light-activated rhodopsin signal in rod photoreceptors. It binds to phosphorylated rhodopsin, preventing further activation of the phototransduction cascade and allowing the eye to recover from light stimulation.

Protein structure: The SAG gene encodes S-arrestin (arrestin-1), a protein consisting of 405 amino acids with a molecular weight of approximately 45 kDa. The protein structure is characterized by two distinct domains: an N-terminal domain and a C-terminal domain, both of which adopt a beta-strand-rich fold. These domains are connected by a flexible hinge region, allowing the protein to undergo significant conformational changes upon binding to its target. The structure of S-arrestin is highly conserved among the arrestin family. It features a polar core that stabilizes the inactive conformation of the protein. Upon interaction with phosphorylated, light-activated rhodopsin, this polar core is disrupted, leading to a conformational change that exposes binding sites for the receptor. S-arrestin does not typically assemble into large functional complexes but functions as a monomer when binding to rhodopsin. However, it can form tetramers in the dark-adapted state, which may serve as a storage form or play a role in its interaction with microtubules during light-dependent translocation.

Molecular function: The SAG gene encodes S-arrestin (also known as arrestin-1 or visual arrestin), a crucial regulatory protein in the visual phototransduction cascade. Its primary molecular function is to quench the light-induced signaling pathway in rod photoreceptors. When a photon of light strikes rhodopsin, it causes a conformational change to its active form, metarhodopsin II, which then activates the G-protein transducin, initiating a signaling cascade that ultimately leads to a change in the membrane potential of the photoreceptor cell. To terminate this signal and allow the photoreceptor to recover and respond to subsequent light stimuli, rhodopsin kinase (GRK1) phosphorylates the activated rhodopsin. S-arrestin then binds specifically to the phosphorylated, light-activated rhodopsin. This binding physically blocks the interaction between rhodopsin and transducin, effectively shutting off the signaling cascade. S-arrestin is highly abundant in rod outer segments and undergoes light-dependent translocation between the inner and outer segments, which is thought to play a role in light adaptation and protecting the photoreceptors from light-induced damage.

Expression pattern: The SAG gene is predominantly expressed in the retina and the pineal gland. Within the retina, expression is highly specific to photoreceptor cells, particularly rod photoreceptors, where the encoded protein, S-arrestin (arrestin-1), is one of the most abundant soluble proteins. It is localized primarily to the outer segments of the photoreceptors, where the phototransduction cascade takes place. Some expression is also observed in cone photoreceptors, although cones have their own specific arrestin (cone arrestin or arrestin-4). During development, SAG expression begins as photoreceptors mature and start to form outer segments, coinciding with the onset of visual function. The high level of expression in the pineal gland is consistent with the evolutionary relationship between the retina and the pineal gland, both of which contain light-sensitive cells and utilize similar phototransduction machinery. There are no major tissue-specific isoforms of SAG, as the primary transcript is highly conserved and specifically tailored for its role in visual signal transduction.

Mutation spectrum: The mutation spectrum of the SAG gene includes a variety of pathogenic variants, such as missense, nonsense, frameshift, splice-site mutations, and large deletions. To date, over 30 pathogenic variants have been reported in the Human Gene Mutation Database (HGMD) and ClinVar. The majority of these are loss-of-function mutations associated with autosomal recessive Oguchi disease or retinitis pigmentosa. A notable hotspot or founder mutation is the c.1147delA (p.Asn383Thrfs*14) variant, which is a frequent cause of Oguchi disease in the Japanese population. Another significant finding is the c.440G>T (p.Cys147Phe) missense mutation, which has been identified as a common founder mutation causing autosomal dominant retinitis pigmentosa in Hispanic families in the Southwestern United States. The spectrum highlights that while null mutations typically cause recessive disease, specific missense changes can lead to dominant pathology.

Pathogenic variants: 1. p.Cys147Phe (c.440G>T) - A well-characterized missense mutation that causes autosomal dominant retinitis pigmentosa. It is a founder mutation frequently found in Hispanic populations in the Southwestern United States and is thought to cause protein misfolding and instability. 2. p.Asn383Thrfs*14 (c.1147delA) - A common frameshift mutation that is a frequent cause of autosomal recessive Oguchi disease, particularly in the Japanese population. It results in a truncated, non-functional protein. 3. p.Arg193* (c.577C>T) - A nonsense mutation that leads to premature truncation of the S-arrestin protein, resulting in a loss of function. It is associated with autosomal recessive Oguchi disease. 4. p.Ser73Pro (c.218C>C) - A missense mutation that has been reported in patients with autosomal recessive retinitis pigmentosa, indicating that certain amino acid substitutions can lead to a progressive degenerative phenotype rather than stationary night blindness.

Clinical significance: Mutations in the SAG gene manifest clinically as two primary inherited retinal diseases: Oguchi disease type 1 and retinitis pigmentosa (RP). Oguchi disease is a rare, autosomal recessive form of congenital stationary night blindness. Patients typically present with non-progressive night blindness from early childhood and exhibit a characteristic golden or silvery-gray discoloration of the fundus that disappears after prolonged dark adaptation (Mizuo-Nakamura phenomenon). Visual acuity, visual fields, and color vision generally remain normal, making it a relatively mild condition compared to other IRDs. In contrast, SAG mutations can also cause retinitis pigmentosa, which can be inherited in either an autosomal recessive (RP47) or autosomal dominant manner. RP is characterized by progressive degeneration of rod and cone photoreceptors, leading to night blindness, progressive loss of peripheral vision (tunnel vision), and eventually central vision loss. The severity and age of onset can vary widely depending on the specific mutation and inheritance pattern. Autosomal dominant RP associated with SAG mutations, such as the p.Cys147Phe variant, often presents with classic RP symptoms and a characteristic golden sheen surrounding posterior pigmentary retinal degeneration.

Inheritance: Autosomal Recessive

Chromosomal location: 2q37.3

Genotype-phenotype correlations: Genotype-phenotype correlations for the SAG gene are primarily defined by the inheritance pattern and the specific nature of the mutation. Biallelic (homozygous or compound heterozygous) loss-of-function mutations, such as nonsense mutations, frameshifts, or large deletions that result in a complete absence of functional S-arrestin, typically cause Oguchi disease type 1. This condition is characterized by a stationary phenotype with night blindness but preserved daytime vision. However, certain missense mutations or specific combinations of variants can lead to the more severe, progressive phenotype of autosomal recessive retinitis pigmentosa (RP47). Furthermore, specific heterozygous missense mutations, most notably the p.Cys147Phe variant, have been identified as causing autosomal dominant retinitis pigmentosa. These dominant mutations likely act through a dominant-negative or toxic gain-of-function mechanism, where the mutant protein interferes with the function of the wild-type protein or causes cellular toxicity due to misfolding and aggregation, leading to progressive photoreceptor degeneration.

Research and therapeutic approaches: Currently, there are no FDA-approved targeted therapies specifically for SAG-related inherited retinal diseases. Management primarily focuses on supportive care, including the use of low-vision aids, mobility training, and regular ophthalmologic monitoring to manage complications such as cataracts or macular edema. For patients with Oguchi disease, avoiding excessive light exposure and allowing for prolonged dark adaptation can help manage symptoms. However, several investigational therapeutic approaches are being explored. Gene augmentation therapy, which involves delivering a functional copy of the SAG gene to the retina using viral vectors (such as adeno-associated virus, AAV), is a promising strategy for autosomal recessive forms of the disease (Oguchi disease and RP47). This approach aims to restore the missing S-arrestin function. For autosomal dominant RP caused by mutations like p.Cys147Phe, gene therapy strategies may need to employ a "knockdown and replace" approach, using RNA interference or CRISPR/Cas9 to silence the mutant allele while simultaneously providing a healthy copy of the gene. Preclinical studies in animal models are ongoing to evaluate the safety and efficacy of these strategies.

Diagnostic testing: Diagnostic testing for SAG gene mutations typically involves comprehensive genetic testing panels for inherited retinal diseases or whole exome sequencing (WES). These tests can identify single nucleotide variants, small insertions/deletions, and large genomic rearrangements in the SAG gene. Clinical diagnosis of Oguchi disease can often be suspected based on the characteristic Mizuo-Nakamura phenomenon observed during fundus examination, but genetic testing is required for definitive confirmation and to distinguish it from other forms of congenital stationary night blindness. Genetic counseling is highly recommended for individuals and families affected by SAG-related IRDs. Counselors can help patients understand the inheritance pattern (autosomal recessive or dominant), the risk of passing the condition to offspring, and the potential clinical course of the disease. For families with known pathogenic variants, carrier testing and prenatal diagnosis may be available options.

Animal models: The primary animal model used to study the SAG gene is the Sag knockout (Sag-/-) mouse. These mice exhibit a complete loss of S-arrestin protein, which leads to prolonged photoreceptor responses to light and increased susceptibility to light-induced retinal degeneration. Studies in these mice have revealed that the absence of arrestin-1 causes the phototransduction cascade to remain active for extended periods, leading to photoreceptor cell death through apoptosis. This model has been crucial for understanding the mechanisms of Oguchi disease and retinitis pigmentosa associated with SAG mutations. Additionally, researchers have developed knock-in mouse models to study specific pathogenic variants, such as the dominant p.Cys147Phe mutation. These models help elucidate how specific amino acid changes affect protein folding, stability, and interaction with rhodopsin, providing insights into the genotype-phenotype correlations observed in human patients. Zebrafish models are also emerging as valuable tools for studying retinal development and the functional consequences of SAG mutations in a more accessible vertebrate system.

Population genetics: The carrier frequency of SAG mutations varies significantly among different populations. In the general population, pathogenic variants in SAG are relatively rare. However, specific founder mutations have led to higher carrier frequencies in certain groups. For example, the c.1147delA mutation is notably prevalent in the Japanese population, contributing to a higher incidence of Oguchi disease in that region. Similarly, the dominant p.Cys147Phe mutation has been identified as a common founder mutation among Hispanic families in the Southwestern United States, suggesting a specific population genetic history for this variant. Overall carrier frequencies for recessive IRD genes, including SAG, highlight the importance of population-specific genetic screening and counseling.

Selected references: 1. Sullivan LS, et al. A Novel Dominant Mutation in SAG, the Arrestin-1 Gene, Is a Common Cause of Retinitis Pigmentosa in Hispanic Families in the Southwestern United States. Invest Ophthalmol Vis Sci, 2017. PMID: 28549094 2. Fuchs S, et al. A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat Genet, 1995. PMID: 7670478 3. Nishiguchi KM, et al. Phenotypic Features of Oguchi Disease and Retinitis Pigmentosa in Patients with S-Antigen Mutations: A Long-Term Follow-up Study. Ophthalmology, 2019. PMID: 31257036 4. Yamaki K, et al. Structural organization of the human S-antigen gene. cDNA, amino acid, intron, exon, promoter, in vitro transcription, retina, and pineal gland. J Biol Chem, 1990. PMID: 2249983 5. Palczewski K, et al. Regulation of rhodopsin dephosphorylation by arrestin. J Biol Chem, 1989. PMID: 2550422 6. Tawfik CA, et al. Mutation analysis reveals novel and known mutations in SAG gene in first two Egyptian families with Oguchi disease. BMC Ophthalmol, 2022. PMID: 35549688